• Phoenix Rising needs funds to operate: please consider donating to support PR

Chronic controversy continues over mysterious XMRV virus

being

Senior Member
Messages
14
Likes
0
Here's a new article in Nature Medicine, anyone got access to fulltext? If so, please pm me. Thanks.

----------------------------------------------

Chronic controversy continues over mysterious XMRV virus
Elie Dolgin
Nature Medicine 16, 832 (2010)
doi:10.1038/nm0810-832a

http://www.nature.com/nm/journal/v16/n8/full/nm0810-832a.html


Last year, a Nevada team linked a peculiar retrovirus to chronic fatigue syndrome (CFS), an elusive condition with no known cause. The virus- known as xenotropic murine leukemia virus-related virus, or XMRV- had previously been implicated in an aggressive form of prostate cancer, but XMRV's role in both diseases has been hotly contested, particularly with regard to CFS.
 

jspotila

Senior Member
Messages
1,099
Likes
778
Here's a new article in Nature Medicine, anyone got access to fulltext? If so, please pm me. Thanks.
The article is only a half page. The text says the following:

Last year, a Nevada team linked a peculiar retrovirus to chronic fatigue syndrome (CFS), an elusive condition with no known cause. The virusknown as xenotropic murine leukemia virusrelated virus, or XMRVhad previously been implicated in an aggressive form of prostate cancer, but XMRVs role in both diseases has been hotly contested, particularly with regard to CFS.

Several research groups have failed to reproduce the initial finding, including a team from the US Centers for Disease Control and Prevention (CDC), but scientists at the National Institutes of Health (NIH) and Food and Drug Administration (FDA) reportedly have unpublished data supporting the link between the mysterious virus and CFS. When the data are published, they will provide a confirmation of our initial discovery, says Judy Mikovits, director of research at the Whittemore Peterson Institute in Reno, Nevada who led the research.

Spurred on by these mixed results, the FDAs blood products advisory committee met for two days in late July to discuss whether the virus poses a safety threat to the blood supply. Here are the facts they had to consider:
This is followed by a timeline going from the Science paper in October 2009 to the Retrovirology paper and PNAS delay in July 2010.